Compare NKLR & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NKLR | SENS |
|---|---|---|
| Founded | 2018 | 1996 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Industrial Machinery/Components |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 464.1M | 397.1M |
| IPO Year | 2025 | 2014 |
| Metric | NKLR | SENS |
|---|---|---|
| Price | $2.31 | $9.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $16.40 | $13.67 |
| AVG Volume (30 Days) | 315.9K | ★ 573.7K |
| Earning Date | 12-06-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,389,000.00 |
| Revenue This Year | N/A | $82.21 |
| Revenue Next Year | N/A | $55.63 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 19.85 |
| 52 Week Low | $1.93 | $4.79 |
| 52 Week High | $8.63 | $10.64 |
| Indicator | NKLR | SENS |
|---|---|---|
| Relative Strength Index (RSI) | 31.05 | 60.42 |
| Support Level | N/A | $5.07 |
| Resistance Level | $5.20 | $10.07 |
| Average True Range (ATR) | 0.19 | 0.55 |
| MACD | 0.05 | 0.11 |
| Stochastic Oscillator | 30.79 | 98.28 |
Terra Innovatum Global NV is a micro modular nuclear solutions company that aims to deliver reliable, low-cost, and zero-carbon power wherever energy demand is present through its first-of-a-kind reactor, SOLO. SOLO is compact yet extremely powerful, with one unit generating 1MWe of power, while designed with the strictest safety characteristics and the ability to run 24/7 without the need to refuel for 15 years. Its modular design aims to achieve maximum energy efficiency while significantly reducing the levelized cost of energy (LCOE). SOLO is built using off-the-shelf components and widely available fuel, low-enriched uranium (LEU), which de-risks its regulatory and commercial pathway.
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.